06:24 AM EDT, 04/23/2026 (MT Newswires) -- Novo Nordisk (NVO) said Thursday a phase 3a trial of oral semaglutide in children and adolescents aged between 10 and 17 years with type-2 diabetes showed a "superior reduction"in a measure of blood sugar control over placebo.

Results also showed a "well-tolerated"safety profile, consistent with prior semaglutide trials, the Danish drugmaker said.

Oral semaglutide is available as Rybelsus in the European Union and the US, and will be available in the US as Ozempic pill "soon,"Novo Nordisk said.

Novo Nordisk ADR

Senast

39,15

1 dag %

0,00%

1 dag

1 mån

1 år

Novo Nordisk B

Senast

249,60

1 dag %

0,24%
Marknadsöversikt

1 DAG %

Senast

1 mån